UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`MILTENYI BIOMEDICINE GmbH and MILTENYI BIOTEC INC.
`Petitioner
`
`v.
`
`THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
`Patent Owner
`
`IPR Trial No. IPR2022-00855
`U.S. Patent No. 9,540,445
`
`DECLARATION OF THOMAS S. FLETCHER
`
`- 1 -
`
`UPenn Ex. 2048
`Miltenyi v. UPenn
`IPR2022-00855
`Page 1
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`MILTENYI BIOMEDICINE GmbH and MILTENYI BIOTEC INC.
`Petitioner
`
`v.
`
`THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
`Patent Owner
`
`IPR Trial No. IPR2022-00855
`U.S. Patent No. 9,540,445
`
`DECLARATION OF THOMAS S. FLETCHER
`
`- 1 -
`
`UPenn Ex. 2048
`Miltenyi v. UPenn
`IPR2022-00855
`Page 1
`
`
`
`
`
`
`
`
`
`
`
`I, Thomas S. Fletcher, make the following Declaration pursuant to 28 U.S.C.
`§ 1746:
`
`1. I am a partner at the law firm of Williams & Connolly LLP, Backup Counsel
`
`for Real Party in Interest and Licensee Novartis Pharma AG. I am a member
`
`of the bars of the State of California and the District of Columbia and
`
`registered to practice in front of the United States Patent and Trademark
`
`Office.
`
`2. I submit this Declaration in connection with the above-identified Inter
`
`Partes Review proceeding of U.S. Patent No. 9,540,445 that has been
`
`instituted at the U.S. Patent and Trademark Office under 35 U.S.C §§ 311-
`
`319, 37 C.F.R. § 42.
`
`3. Exhibit 2001 is a true and correct copy of Jason Fagone, Has Carl June
`
`Found a Key to Fighting Cancer?, PHILA. MAG. (Aug. 1, 2013), which
`
`was downloaded from NewsBank and can be accessed behind a paywall at
`
`the URL https://www.newsbank.com/. An exhibit label and page number
`
`have been added to the bottom right corner of this document, but no other
`
`alterations have been made.
`
`4. Exhibit 2002 is a true and correct copy of Denise Grady, An Immune System
`
`Trained to Kill Cancer, N.Y. TIMES (Sept. 12, 2011), which was accessed
`
`via the URL https://www.nytimes.com/2011/09/13/health/13gene.html and
`
`printed to PDF. The article is now permanently accessible at the URL
`
`- 2 -
`
`UPenn Ex. 2048
`Miltenyi v. UPenn
`IPR2022-00855
`Page 2
`
`
`
`
`
`
`
`https://perma.cc/58EM-KPT5. An exhibit label and page number have been
`
`added to the bottom right corner of this document, but no other alterations
`
`have been made.
`
`5. Exhibit 2003 is a true and correct copy of Jasone Fagone, Walt Keller,
`
`Leukemia Survivor, Has Passed, PHILA. MAG. (Feb. 20, 2014), which was
`
`accessed via the URL https://www.phillymag.com/news/2014/02/20/walt-
`
`keller-leukemia-survivor-obituary-1953-2014/ and printed to PDF. The
`
`article is now permanently accessible at the URL https://perma.cc/5CL7-
`
`ZPHV. An exhibit label and page number have been added to the bottom
`
`right corner of this document, but no other alterations have been made.
`
`6. Exhibit 2004 is a true and correct copy of Gina Kolata, A Cancer Treatment
`
`Makes Leukemia Vanish, but Creates More Mysteries, N.Y. TIMES (Feb. 2,
`
`2022), which was accessed via the URL
`
`https://www.nytimes.com/2022/02/02/health/leukemia-car-t-
`
`immunotherapy.html and printed to PDF. The article is now permanently
`
`accessible at the URL https://perma.cc/UV2W-PGCN. An exhibit label and
`
`page number have been added to the bottom right corner of this document,
`
`but no other alterations have been made.
`
`7. Exhibit 2005 is a true and correct copy of Denise Grady, In Girl’s Last Hope,
`
`Altered Immune Cells Beat Leukemia, N.Y. TIMES (Dec. 9, 2012), which
`
`was accessed via the URL https://www.nytimes.com/2012/12/10/health/a-
`- 3 -
`
`
`
`UPenn Ex. 2048
`Miltenyi v. UPenn
`IPR2022-00855
`Page 3
`
`
`
`
`
`
`
`
`
`breakthrough-against-leukemia-using-altered-t-cells.html and printed to
`
`PDF. The article is now permanently accessible at the URL
`
`https://perma.cc/NUD3-B43D. An exhibit label and page number have been
`
`added to the bottom right corner of this document, but no other alterations
`
`have been made.
`
`8. Exhibit 2006 is a true and correct copy of Denise Grady, F.D.A. Approves
`
`First Gene-Altering Leukemia Treatment, Costing $475,000, N.Y. TIMES
`
`(Aug. 30, 2017), which was accessed via the URL
`
`https://www.nytimes.com/2017/08/30/health/gene-therapy-cancer.html and
`
`printed to PDF. The article is now permanently accessible at the URL
`
`https://perma.cc/6T4Q-9W8D. An exhibit label and page number have been
`
`added to the bottom right corner of this document, but no other alterations
`
`have been made.
`
`9. Exhibit 2007 is a true and correct copy of FOOD AND DRUG ADMIN.,
`
`FDA APPROVAL BRINGS FIRST GENE THERAPY TO THE UNITED
`
`STATES (Aug. 30, 2017), which was accessed via the URL
`
`https://www.fda.gov/news-events/press-announcements/fda-approval-
`
`brings-first-gene-therapy-united-states and printed to PDF. The article is
`
`now permanently accessible at the URL https://perma.cc/26LT-ESRX. An
`
`exhibit label and page number have been added to the bottom right corner of
`
`this document, but no other alterations have been made.
`- 4 -
`
`UPenn Ex. 2048
`Miltenyi v. UPenn
`IPR2022-00855
`Page 4
`
`
`
`
`
`
`
`
`
`10. Exhibit 2008 is a true and correct copy of FOOD AND DRUG ADMIN.,
`
`BREAKTHROUGH THERAPY (Jan. 4, 2018), which was accessed via the
`
`URL https://www.fda.gov/patients/fast-track-breakthrough-therapy-
`
`accelerated-approval-priority-review/breakthrough-therapy and printed to
`
`PDF. The article is now permanently accessible at the URL
`
`https://perma.cc/FE35-UMTZ. An exhibit label and page number have been
`
`added to the bottom right corner of this document, but no other alterations
`
`have been made.
`
`11. Exhibit 2009 is a true and correct copy of FOOD AND DRUG
`
`ADMIN., PRIORITY REVIEW (Jan. 4, 2018), which was accessed via
`
`the URL https://www.fda.gov/patients/fast-track-breakthrough-therapy-
`
`accelerated-approval-priority-review/priority-review and printed to
`
`PDF. The article is now permanently accessible at the URL
`
`https://perma.cc/HCV8-DDH6. An exhibit label and page number have
`
`been added to the bottom right corner of this document, but no other
`
`alterations have been made.
`
`12. Exhibit 2010 is a true and correct certified copy of Barbara Savoldo et al.,
`
`CD28 costimulation improves expansion and persistence of chimeric antigen
`
`receptor-modified T cells in lymphoma patients, 121 J. CLINICAL
`
`INVESTIGATION 1822 (2011), which was accessed via the URL
`
`https://www.jci.org/articles/view/46110/pdf and printed to PDF. The article
`
`- 5 -
`
`UPenn Ex. 2048
`Miltenyi v. UPenn
`IPR2022-00855
`Page 5
`
`
`
`
`
`
`
`
`
`is now permanently accessible at the URL https://perma.cc/UP9X-5BQ3. An
`
`exhibit label and page number have been added to the bottom right corner of
`
`this document, but no other alterations have been made.
`
`13. Exhibit 2011 is a true and correct copy of Brian G. Till et al., Adoptive
`
`immunotherapy for indolent non-Hodgkin lymphoma and mantle cell
`
`lymphoma using genetically modified autologous CD20-specific T cells, 112
`
`BLOOD 2261 (2008), which was accessed via the URL
`
`https://ashpublications.org/blood/article-
`
`pdf/112/6/2261/1482883/zh801808002261.pdf and printed to PDF. The
`
`article is now permanently accessible at the URL https://perma.cc/C8VW-
`
`8PRT. An exhibit label and page number have been added to the bottom
`
`right corner of this document, but no other alterations have been made.
`
`14. Exhibit 2012 is a true and correct copy of Renier J. Brentjens et al., Safety
`
`and persistence of adoptively transferred autologous CD19-targeted T cells
`
`in patients with relapsed or chemotherapy refractory B-cell leukemias, 118
`
`BLOOD 4817 (2011), which was downloaded from the journal website, and
`
`is accessible behind a paywall at https://ashpublications.org/blood. An
`
`exhibit label and page number have been added to the bottom right corner of
`
`this document, but no other alterations have been made.
`
`15. Exhibit 2013 is a true and correct copy of Renier Brentjens et al., Treatment
`
`of chronic lymphocytic leukemia with genetically targeted autologous T
`
`- 6 -
`
`UPenn Ex. 2048
`Miltenyi v. UPenn
`IPR2022-00855
`Page 6
`
`
`
`
`
`
`
`
`
`cells: case report of an unforeseen adverse event in a phase I clinical trial,
`
`18 MOLECULAR THERAPY 666 (2010), which was accessed via the
`
`URL https://www.cell.com/action/showPdf?pii=S1525-
`
`0016%2816%2932320-6 and printed to PDF. The article is now
`
`permanently accessible at the URL https://perma.cc/R4QK-MCPH. An
`
`exhibit label and page number have been added to the bottom right corner of
`
`this document, but no other alterations have been made.
`
`16. Exhibit 2014 is a true and correct copy of Renier J. Brentjens et al., A Phase
`
`I Trial for the Treatment of Chemo refractory Chronic Lymphocytic
`
`Leukemia with CD19-Targeted Autologous T Cells, 16 MOLECULAR
`
`THERAPY S15 (2008), which was accessed via the URL
`
`https://www.cell.com/action/showPdf?pii=S1525-0016%2816%2939441-2
`
`and printed to PDF. The article is now permanently accessible at the URL
`
`https://perma.cc/Z96K-WXU2. An exhibit label and page number have been
`
`added to the bottom right corner of this document, but no other alterations
`
`have been made.
`
`17. Exhibit 2015 is a true and correct copy of Jennifer Couzin-Frankel, The
`
`dizzying journey to a new cancer arsenal, 340 SCI. 1514 (2013), which was
`
`downloaded from the journal website, and is accessible behind a paywall at
`
`https://www.science.org/. An exhibit label and page number have been
`
`added to the bottom right corner of this document, but no other alterations
`
`- 7 -
`
`UPenn Ex. 2048
`Miltenyi v. UPenn
`IPR2022-00855
`Page 7
`
`
`
`
`
`
`
`
`
`have been made.
`
`18. Exhibit 2016 is a true and correct copy of Jennifer Couzin-Frankel,
`
`Breakthrough of the Year 2013: Cancer Immunotherapy, 342 SCI. 1432
`
`(2013), which was accessed via the URL
`
`https://www.science.org/doi/reader/10.1126/science.342.6165.1432 and
`
`printed to PDF. The article is now permanently accessible at the URL
`
`https://perma.cc/5HSG-2PXX. An exhibit label and page number have been
`
`added to the bottom right corner of this document, but no other alterations
`
`have been made.
`
`19. Exhibit 2017 is a true and correct copy of David L. Porter et al., Chimeric
`
`Antigen Receptor Modified T Cells Directed Against CD 19 (CTL0l 9 cells)
`
`Have Long-Term Persistence And Induce Durable Responses In Relapsed,
`
`Refractory CLL, 122 BLOOD 4162 (2013), which was accessed via the
`
`URL https://doi.org/10.1182/blood.V122.21.4162.4162 and printed to PDF.
`
`The article is now permanently accessible at the URL
`
`https://perma.cc/Q37K-TBLJ. An exhibit label and page number have been
`
`added to the bottom right corner of this document, but no other alterations
`
`have been made.
`
`20. Exhibit 2018 is a true and correct copy of David L. Porter et al.,
`
`Randomized, Phase II Dose Optimization Study Of Chimeric Antigen
`
`Receptor Modified T Cells Directed Against CD 19 (CTL019) In Patients
`
`- 8 -
`
`UPenn Ex. 2048
`Miltenyi v. UPenn
`IPR2022-00855
`Page 8
`
`
`
`
`
`
`
`
`
`With Relapsed Refractory CLL, 122 BLOOD 873 (2013), which was
`
`accessed via the URL https://doi.org/10.1182/blood.V124.21.1982.1982 and
`
`printed to PDF. The article is now permanently accessible at the URL
`
`https://perma.cc/VH3U-PHED. An exhibit label and page number have been
`
`added to the bottom right corner of this document, but no other alterations
`
`have been made.
`
`21. Exhibit 2019 is a true and correct copy of Stephan A. Grupp et al., T Cells
`
`Engineered With A Chimeric Antigen Receptor (CAR) Targeting CD 19
`
`(CTL0l 9) Produce Significant In Vivo Proliferation, Complete Responses
`
`And Long-Term Persistence Without GVHD In Children And Adults With
`
`Relapsed, Refractory ALL, 122 BLOOD 67 (2013), which was accessed via
`
`the URL https://doi.org/10.1182/blood.V122.21.67.67 and printed to PDF.
`
`The article is now permanently accessible at the URL
`
`https://perma.cc/A2UW-HG6Z. An exhibit label and page number have been
`
`added to the bottom right corner of this document, but no other alterations
`
`have been made.
`
`22. Exhibit 2020 is a true and correct copy of James N. Kochenderfer et al., B-
`
`cell depletion and remissions of malignancy along with cytokine-associated
`
`toxicity in a clinical trial of anti-CD 19 chimeric-antigen-receptor
`
`transduced T cells, 119 BLOOD 2709 (2012), which was accessed via the
`
`URL http://ashpublications.org/blood/article-
`
`- 9 -
`
`UPenn Ex. 2048
`Miltenyi v. UPenn
`IPR2022-00855
`Page 9
`
`
`
`
`
`
`
`
`
`pdf/119/12/2709/1350836/zh801212002709.pdf and printed to PDF. The
`
`article is now permanently accessible at the URL https://perma.cc/XV8C-
`
`2MB6. An exhibit label and page number have been added to the bottom
`
`right corner of this document, but no other alterations have been made.
`
`23. Exhibit 2021 is a true and correct copy of Carl June Named One of Time’s
`
`100 Most Influential People in the World, PENN MEDICINE (Apr. 26,
`
`2018), which was accessed via the URL
`
`https://pathology.med.upenn.edu/news/carl-june-named-one-times-100-
`
`most-influential-people-world and printed to PDF. The article is now
`
`permanently accessible at the URL https://perma.cc/53EQ-PAA6. An
`
`exhibit label and page number have been added to the bottom right corner of
`
`this document, but no other alterations have been made.
`
`24. Exhibit 2022 is a true and correct copy of Holly Auer, Penn Medicine
`
`Immunotherapy Pioneer Carl June, MD, Awarded 2015 Paul Ehrlich and
`
`Ludwig Darmstaedter Prize, PENN TODAY (Mar. 11, 2015), which was
`
`accessed via the URL https://penntoday.upenn.edu/news/penn-medicine-
`
`immunotherapy-pioneer-carl-june-md-awarded-2015-paul-ehrlich-and-
`
`ludwig-darmstaed and printed to PDF. The article is now permanently
`
`accessible at the URL https://perma.cc/J3ZX-6U5P. An exhibit label and
`
`page number have been added to the bottom right corner of this document,
`
`but no other alterations have been made.
`
`- 10 -
`
`UPenn Ex. 2048
`Miltenyi v. UPenn
`IPR2022-00855
`Page 10
`
`
`
`
`
`
`
`
`
`25. Exhibit 2023 is a true and correct copy of Andrew Pollock, Setting the
`
`Body’s ‘Serial Killers’ Loose on Cancer, N.Y. TIMES (Aug. 1, 2016),
`
`which was accessed via the URL
`
`https://www.nytimes.com/2016/08/02/health/cancer-cell-therapy-immune-
`
`system.html and printed to PDF. The article is now permanently accessible
`
`at the URL https://perma.cc/8627-LFXZ. An exhibit label and page number
`
`have been added to the bottom right corner of this document, but no other
`
`alterations have been made.
`
`26. Exhibit 2024 is a true and correct copy of 2015 Watanabe Award Winner
`
`Carl H. June, IND. CLINICAL AND TRANSLATIONAL SCIS. INST.,
`
`which was accessed via the URL https://indianactsi.org/awards/watanabe-
`
`award-winners/2015-watanabe-award-winner-carl-h-june/ and printed to
`
`PDF. The article is now permanently accessible at the URL
`
`https://perma.cc/8C7V-82UD. An exhibit label and page number have been
`
`added to the bottom right corner of this document, but no other alterations
`
`have been made.
`
`27. Exhibit 2025 is a true and correct copy of Agilent Presents Thought Leader
`
`Award to Drs. Carl H. June and Michael Milone, AGILENT TECHS. INC.
`
`(Nov. 17, 2020), which was accessed via the URL
`
`https://www.agilent.com/about/newsroom/presrel/2020/17nov-ca20030.html
`
`and printed to PDF. The article is now permanently accessible at the URL
`
`- 11 -
`
`UPenn Ex. 2048
`Miltenyi v. UPenn
`IPR2022-00855
`Page 11
`
`
`
`
`
`
`
`
`
`https://perma.cc/Y5XK-P9XV. An exhibit label and page number have been
`
`added to the bottom right corner of this document, but no other alterations
`
`have been made.
`
`28. Exhibit 2028 is a true and correct copy of World Intell. Prop. Org. Patent
`
`Application No. WO 02/077029 A2, which was downloaded as a PDF via
`
`the URL
`
`https://patentimages.storage.googleapis.com/ef/37/cd/ac3bb81b2861a9/WO
`
`2002077029A2.pdf. An exhibit label and page number have been added to
`
`the bottom right corner of this document, but no other alterations have been
`
`made.
`
`29. Exhibit 2029 is a true and correct certified copy of Pilot Study for Patients
`
`with Chemotherapy Resistant or Refractory CD19 Leukemia and Lymphoma
`
`(CART-19), CLINICALTRIALS.GOV (April 29, 2009), which was
`
`accessed via the URL
`
`http://web.archive.org/web/20090903002304/http://clinicaltrials.gov/ct2/sho
`
`w/NCT00891215 and printed to PDF. The article is now permanently
`
`accessible at the URL https://perma.cc/9XCR-AK6R. An exhibit label and
`
`page number have been added to the bottom right corner of this document,
`
`but no other alterations have been made.
`
`30. Exhibit 2031 is a true and correct copy of Steven A. Rosenberg et al., Use of
`
`Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of
`
`- 12 -
`
`UPenn Ex. 2048
`Miltenyi v. UPenn
`IPR2022-00855
`Page 12
`
`
`
`
`
`
`
`
`
`Patients with Metastatic Melanoma, 319 NEW ENG. J. MED. 1676 (1988),
`
`which was downloaded from the journal website, and is accessible behind a
`
`paywall at https://www.nejm.org/. An exhibit label and page number have
`
`been added to the bottom right corner of this document, but no other
`
`alterations have been made.
`
`31. Exhibit 2032 is a true and correct copy of Michael C. Jensen et al.,
`
`Antitransgene Rejection Responses Contribute to Attenuated Persistence of
`
`Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor
`
`Redirected T Cells in Humans, 16 BIOLOGY BLOOD AND MARROW
`
`TRANSPLANTATION 1245 (2010), which was accessed via the URL
`
`https://www.astctjournal.org/action/showPdf?pii=S1083-
`
`8791%2810%2900119-9 and printed to PDF. The article is now
`
`permanently accessible at the URL https://perma.cc/L4C7-6FVD. An
`
`exhibit label and page number have been added to the bottom right corner of
`
`this document, but no other alterations have been made.
`
`32. Exhibit 2033 is a true and correct copy of Richard A. Morgan et al., Case
`
`Report of a Serious Adverse Event Following the Administration of T Cells
`
`Transduced With a Chimeric Antigen Receptor Recognizing ERBB2, 18
`
`MOLECULAR THERAPY 843 (2010), which was accessed via the URL
`
`https://www.cell.com/action/showPdf?pii=S1525-0016%2816%2932342-5
`
`and printed to PDF. The article is now permanently accessible at the URL
`
`- 13 -
`
`UPenn Ex. 2048
`Miltenyi v. UPenn
`IPR2022-00855
`Page 13
`
`
`
`
`
`
`
`
`
`https://perma.cc/TFX5-D5W3. An exhibit label and page number have been
`
`added to the bottom right corner of this document, but no other alterations
`
`have been made.
`
`33. Exhibit 2034 is a true and correct copy of David L. Porter et al., A phase 1
`
`trial of donor lymphocyte infusions expanded and activated ex vivo via
`
`CD3/CD28 costimulation, 107 BLOOD 1325 (2006), which was accessed
`
`via the URL
`
`https://www.sciencedirect.com/science/article/pii/S0006497120663819/pdfft
`
`?md5=71c1c9655096c9d57eef2490a3cc20a2&pid=1-s2.0-
`
`S0006497120663819-main.pdf and printed to PDF. The article is now
`
`permanently accessible at the URL https://perma.cc/9TRY-KHUZ. An
`
`exhibit label and page number have been added to the bottom right corner of
`
`this document, but no other alterations have been made.
`
`34. Exhibit 2035 is a true and correct copy of Grazyna Lipowska-Bhalla,
`
`Targeted immunotherapy of cancer with CAR T cells: achievements and
`
`challenges, 61 CANCER IMMUNOLOGY, IMMUNOTHERAPY 953
`
`(2012), which was accessed via the URL
`
`https://link.springer.com/article/10.1007/s00262-012-1254-0 and printed to
`
`PDF. An exhibit label and page number have been added to the bottom right
`
`corner of this document, but no other alterations have been made.
`
`35. Exhibit 2036 is a true and correct copy of Latest paper from the father of
`
`- 14 -
`
`UPenn Ex. 2048
`Miltenyi v. UPenn
`IPR2022-00855
`Page 14
`
`
`
`
`
`
`
`
`
`CAR-T: CAR-T really completely cured cancer, MEDICALTREND.ORG,
`
`which was accessed via the URL https://medicaltrend.org/2022/02/03/latest-
`
`paper-from-the-father-of-car-t-car-t-really-completely-cured-cancer/ and
`
`printed to PDF. The article is now permanently accessible at the URL
`
`https://perma.cc/Q63N-5MZZ. An exhibit label and page number have been
`
`added to the bottom right corner of this document, but no other alterations
`
`have been made.
`
`36. Exhibit 2037 is a true and correct copy of Bipulendu Jena et al., Redirecting
`
`T-cell specificity by introducing a tumor-specific chimeric antigen receptor,
`
`116 BLOOD 1035 (2010), which was accessed via the URL
`
`https://ashpublications.org/blood/article-
`
`pdf/116/7/1035/1333755/zh803310001035.pdf and printed to PDF. The
`
`article is now permanently accessible at the URL https://perma.cc/A9UN-
`
`FALF. An exhibit label and page number have been added to the bottom
`
`right corner of this document, but no other alterations have been made.
`
`37. Exhibit 2038 is a true and correct copy of Michael H. Kershaw et al., A
`
`Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for
`
`Ovarian Cancer, 12 CLINICAL CANCER RSCH. 6106 (2006), which was
`
`accessed via the URL https://aacrjournals.org/clincancerres/article-
`
`pdf/12/20/6106/1965492/6106.pdf and printed to PDF. The article is now
`
`permanently accessible at the URL https://perma.cc/Y8G3-44H9. An exhibit
`
`- 15 -
`
`UPenn Ex. 2048
`Miltenyi v. UPenn
`IPR2022-00855
`Page 15
`
`
`
`
`
`
`
`
`
`label and page number have been added to the bottom right corner of this
`
`document, but no other alterations have been made.
`
`38. Exhibit 2039 is a true and correct copy of Cor H.J. Lamers et al., Treatment
`
`of Metastatic Renal Cell Carcinoma With Autologous T-Lymphocytes
`
`Genetically Retargeted Against Carbonic Anhydrase IX: First Clinical
`
`Experience, 24 J. CLINICAL ONCOLOGY e20 (2006), which was accessed
`
`via the URL
`
`https://ascopubs.org/doi/pdf/10.1200/JCO.2006.05.9964?role=tab and
`
`printed to PDF. The article is now permanently accessible at the URL
`
`https://perma.cc/J3R6-4FWD. An exhibit label and page number have been
`
`added to the bottom right corner of this document, but no other alterations
`
`have been made.
`
`39. Exhibit 2040 is a true and correct copy of ASH honors Bruce R. Blazar,
`
`M.D., and Carl H. June, M.D., with 2012 Ernest Beutler Lecture and Prize,
`
`SCIENCEX (Aug. 27, 2012), which was accessed via the URL
`
`https://sciencex.com/wire-news/107531358/ash-honors-bruce-r-blazar-md-
`
`and-carl-h-june-md-with-2012-ernest.html and printed to PDF. The article is
`
`now permanently accessible at the URL https://perma.cc/NR7V-86KJ. An
`
`exhibit label and page number have been added to the bottom right corner of
`
`this document, but no other alterations have been made.
`
`40. Exhibit 2041 is a true and correct copy of Renier J. Brentjens et al.,
`
`- 16 -
`
`UPenn Ex. 2048
`Miltenyi v. UPenn
`IPR2022-00855
`Page 16
`
`
`
`
`
`
`
`
`
`Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic
`
`Leukemia Xenografts, 13 CLINICAL CANCER RSCH. 5426 (2007), which
`
`was accessed via the URL https://aacrjournals.org/clincancerres/article-
`
`pdf/13/18/5426/1972030/5426.pdf and printed to PDF. The article is now
`
`permanently accessible at the URL https://perma.cc/LX5K-Z86V. An
`
`exhibit label and page number have been added to the bottom right corner of
`
`this document, but no other alterations have been made.
`
`41. Exhibit 2042 is a true and correct copy of U.S. Patent No. 7,402,431, which
`
`was downloaded as a PDF via the URL https://patentcenter.uspto.gov/. An
`
`exhibit label and page number have been added to the bottom right corner of
`
`this document, but no other alterations have been made.
`
`42. Exhibit 2043 is a true and correct copy of Cancer treatment myths: Any
`
`truth to these common beliefs?, MAYO CLINIC (March 22, 2022), which
`
`was accessed via the URL https://www.mayoclinic.org/diseases-
`
`conditions/cancer/in-depth/cancer/art-20046762 and printed to PDF. The
`
`article is now permanently accessible at the URL https://perma.cc/6VDG-
`
`YS55. An exhibit label and page number have been added to the bottom
`
`right corner of this document, but no other alterations have been made.
`
`43. Exhibit 2045 is a true and correct copy of SITC Smalley Award 2013
`
`Recipient, SOC’Y FOR IMMUNOTHERAPY OF CANCER, which was
`
`accessed via the URL https://www.sitcancer.org/funding/named-funds-and-
`
`- 17 -
`
`UPenn Ex. 2048
`Miltenyi v. UPenn
`IPR2022-00855
`Page 17
`
`
`
`
`
`
`
`
`
`awards2/smalley/2013 and printed to PDF. The article is now permanently
`
`accessible at the URL https://perma.cc/3WZF-CH3F. An exhibit label and
`
`page number have been added to the bottom right corner of this document,
`
`but no other alterations have been made.
`
`44. Exhibit 2046 is a true and correct copy of AAI-Steinman Award for Human
`
`Immunology Research Past Recipients, AM. ASS’N OF
`
`IMMUNOLOGISTS, which was accessed via the URL
`
`https://www.aai.org/Awards/Career-Awards/AAI-Steinman-Award-for-
`
`Human-Immunology-Research/Past-Recipients.aspx and printed to PDF.
`
`The article is now permanently accessible at the URL
`
`https://perma.cc/3PCP-UG43. An exhibit label and page number have been
`
`added to the bottom right corner of this document, but no other alterations
`
`have been made.
`
`45. Exhibit 2047 is a true and correct copy of File History of the ’445 Patent,
`
`which was downloaded as a PDF via the URL
`
`https://patentcenter.uspto.gov/. An exhibit label and page number have been
`
`added to the bottom right corner of this document, but no other alterations
`
`have been made.
`
`- 18 -
`
`UPenn Ex. 2048
`Miltenyi v. UPenn
`IPR2022-00855
`Page 18
`
`
`
`
`
`I declare under penalty of perjury under the law of the United States of
`
`America that the foregoing is true and correct.
`
`Dated: November 8, 2022
`
` /s/ Thomas S. Fletcher
`Thomas S. Fletcher
`Reg. No. 72,383
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`- 19 -
`
`UPenn Ex. 2048
`Miltenyi v. UPenn
`IPR2022-00855
`Page 19
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
